Generic Drug Sector Struggles Even As The Need For Cheaper Drugs Grows

Lower prices for generic drugs in the US are continuing to drag on revenues of drug makers like Teva, Sandoz, Mylan and Endo. Industry leaders say the US market is stabilizing, but price erosion and other negative factors impacted second quarter financials across the sector. Teva is attempting a turnaround and Mylan is exploring strategic alternatives.

Generics

Generic drug companies have been trying to navigate through the persistent problem of US drug pricing pressure, but the issue has yet to resolve. Second quarter financials at generic drug manufacturers like Teva Pharmaceutical Industries Ltd., Sandoz International GMBH, Mylan NV and others were weighed down by the US market, due to continued pricing pressure, slow uptake of new complex generics and other company-specific factors.

Price erosion, spurred by customer consolidation and the US FDA's faster ANDA approvals, has impacted generic drug revenues negatively for...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Earnings

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.